News Overview

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

May 24, 2024

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

This collaboration would bring together Renovaro's proprietary cancer vaccine technology and the Cancer Center's expertise in several ancillary immunomodulatory technologies, towards innovative advancements in cancer treatment.

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

April 30, 2024

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI

April 29, 2024

Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI

The potential impact of AI on healthcare is vast and transformative. With the use of AI platforms for diagnosing diseases like cancer, we can expect improved accuracy, efficiency, and outcomes in patient care. Renovaro stands at the forefront of this innovative shift towards a more intelligent healthcare system powered by artificial intelligence.

RenovaroCube to Acquire 100% Ownership of Cyclomics

April 24, 2024

RenovaroCube to Acquire 100% Ownership of Cyclomics

RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.

Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board

April 18, 2024

Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board

This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.

Statement of Renovaro Inc

February 14, 2024

Statement of Renovaro Inc

We felt compelled to comment on the shorter Hindenburg’s opinion piece.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

February 13, 2024

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.

AI Pioneer GEDiCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

February 13, 2024

AI Pioneer GEDiCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

“We believe this combination marks a significant milestone in the journey of personalized medicine,”

Results Shareholders Meeting

January 25, 2024

Results Shareholders Meeting

All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.

Message from CEO The Hon. Mark Dybul, MD

January 16, 2024

Message from CEO The Hon. Mark Dybul, MD

I write to update you on our key developments towards precision medicine for healthy longevity - starting with cancer - powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery towards our vision of a world with effective cancer treatments free from toxic chemotherapy.